MoonLake Immunotherapeutics (MLTX) Earnings Analysis
MoonLake Immunotherapeutics (MLTX) has no confirmed upcoming earnings date. Last quarter (2026-05-11) it missed with EPS -0.98 USD vs -0.91 USD est (-7.7%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -4.88.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does MLTX next report earnings?
No confirmed upcoming earnings date is currently scheduled for MLTX. This page updates as the calendar is published.
MLTX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.98 USD | -0.91 USD | -7.7% | Miss |
| 2026-02-25 | -0.92 USD | -0.92 USD | 0% | Beat |
| 2025-05-12 | -0.63 USD | -0.76 USD | +17.1% | Beat |
| 2025-02-26 | -0.72 USD | -0.53 USD | -35.8% | Miss |
Beat rate: 2/4 (50%) over reported quarters with consensus data.
MLTX valuation and analyst view
| Trailing P/E | -4.88 |
|---|---|
| Trailing EPS | -3.60699 USD |
| Price / book | 5.31 |
| Dividend yield | 0.00% |
| Market cap | 1.58B |
| Analyst consensus | Buy (15 buy / 2 hold / 2 sell) |
| Avg price target | 45 USD |
Related research pages
Frequently asked questions
When is MoonLake Immunotherapeutics (MLTX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for MLTX. This page updates as the calendar is published.
Did MLTX beat earnings last quarter?
In its 2026-05-11 report, MLTX posted EPS of -0.98 USD versus a -0.91 USD estimate — a miss of 7.7%.
What is MLTX's earnings track record?
Over the last 4 reported quarters with consensus data, MLTX beat estimates 2 times (50%).
What is MLTX's current P/E ratio and EPS?
MLTX trades at a trailing P/E of -4.88 on trailing EPS of -3.606985190178979 USD.
What do analysts rate MLTX?
Analyst consensus is "Buy" across 19 ratings (0 strong buy, 15 buy, 2 hold, 2 sell, 0 strong sell). Average 12-month price target: 45 USD.